Fondazione Irccs Ca Granda Ospedale Maggiore

Milan 20122

3 studies enrolling now · 16 studies all time

What they study most

Atopic Dermatitis, Autoimmune Hemolytic Anemia, B-Cell Malignancies, Becker Muscular Dystrophy, Chronic Graft-versus-host Disease, ET (Essential Thrombocythemia), Metastatic Urothelial Carcinoma, Myelodysplastic Syndrome, Myelodysplastic/Myeloproliferative Neoplasm Overlap Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Myeloproliferative Neoplasms

Studies at this site

• A Study to Evaluate INCA035784 in Participants With Myeloproliferative Neoplasms — Recruiting now
• A Study to Evaluate the Safety, Tolerability of INCB160058 in Participants With Myeloproliferative Neoplasms — Recruiting now
• Open-Label Extension of EDG-5506 in Participants With Becker Muscular Dystrophy — Enrolling by invitation
• Rollover Study to Provide Continued Treatment for Participants With B-Cell Malignancies Previously Enrolled in Studies of Parsaclisib (INCB050465) — Running, not enrolling
• A Study to Assess the Efficacy and Safety of Ruxolitinib Cream in Children and Adolescents (6 to <18 Years Old) With Moderate Atopic Dermatitis — Running, not enrolling
• A Study to Evaluate the Efficacy, and Safety Study of Ruxolitinib Cream in Adults With Moderate Atopic Dermatitis — Completed
• Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms — Running, not enrolling
• A Study to Evaluate Efficacy and Safety of Povorcitinib in Participants With Nonsegmental Vitiligo (STOP-V2) — Running, not enrolling
• A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN) — Completed
• Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) — Stopped early
• Carboplatin-paclitaxel With Retifanlimab or Placebo in Participants With Locally Advanced or Metastatic Squamous Cell Anal Carcinoma (POD1UM-303/InterAACT 2). — Completed
• To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313) — Stopped early
• GRAVITAS-309: Itacitinib and Corticosteroids as Initial Treatment for Chronic Graft-Versus-Host Disease — Stopped early
• To Evaluate Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis Who Have Suboptimal Response to Ruxolitinib (LIMBER-304) — Stopped early
• A Study of INCB050465 in Participants With Autoimmune Hemolytic Anemia — Completed
• Treatment of Graves' Orbitopathy to Reduce Proptosis With Teprotumumab Infusions in an Open-Label Clinical Extension Study — Completed